JP2020536931A5 - - Google Patents

Info

Publication number
JP2020536931A5
JP2020536931A5 JP2020520646A JP2020520646A JP2020536931A5 JP 2020536931 A5 JP2020536931 A5 JP 2020536931A5 JP 2020520646 A JP2020520646 A JP 2020520646A JP 2020520646 A JP2020520646 A JP 2020520646A JP 2020536931 A5 JP2020536931 A5 JP 2020536931A5
Authority
JP
Japan
Application number
JP2020520646A
Other languages
Japanese (ja)
Other versions
JPWO2019074826A5 (https=
JP7774958B2 (ja
JP2020536931A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/054825 external-priority patent/WO2019074826A2/en
Publication of JP2020536931A publication Critical patent/JP2020536931A/ja
Priority to JP2025120922A priority Critical patent/JP2025165977A/ja
Publication of JP2020536931A5 publication Critical patent/JP2020536931A5/ja
Publication of JPWO2019074826A5 publication Critical patent/JPWO2019074826A5/ja
Application granted granted Critical
Publication of JP7774958B2 publication Critical patent/JP7774958B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020520646A 2017-10-13 2018-10-08 二層医薬錠剤製剤 Active JP7774958B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025120922A JP2025165977A (ja) 2017-10-13 2025-07-18 二層医薬錠剤製剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762571863P 2017-10-13 2017-10-13
US62/571,863 2017-10-13
US201862634317P 2018-02-23 2018-02-23
US62/634,317 2018-02-23
PCT/US2018/054825 WO2019074826A2 (en) 2017-10-13 2018-10-08 FORMULATION OF BICOLET PHARMACEUTICAL TABLET

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025120922A Division JP2025165977A (ja) 2017-10-13 2025-07-18 二層医薬錠剤製剤

Publications (4)

Publication Number Publication Date
JP2020536931A JP2020536931A (ja) 2020-12-17
JP2020536931A5 true JP2020536931A5 (https=) 2025-09-11
JPWO2019074826A5 JPWO2019074826A5 (https=) 2025-09-11
JP7774958B2 JP7774958B2 (ja) 2025-11-25

Family

ID=66101717

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020520646A Active JP7774958B2 (ja) 2017-10-13 2018-10-08 二層医薬錠剤製剤
JP2025120922A Pending JP2025165977A (ja) 2017-10-13 2025-07-18 二層医薬錠剤製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025120922A Pending JP2025165977A (ja) 2017-10-13 2025-07-18 二層医薬錠剤製剤

Country Status (18)

Country Link
US (1) US20200230141A1 (https=)
EP (2) EP4667003A3 (https=)
JP (2) JP7774958B2 (https=)
KR (2) KR20200070246A (https=)
CN (2) CN117281788A (https=)
AU (1) AU2018347990B2 (https=)
BR (1) BR112020006783A2 (https=)
CA (1) CA3078624A1 (https=)
CL (1) CL2020000959A1 (https=)
ES (1) ES3056013T3 (https=)
FI (1) FI3694522T3 (https=)
IL (1) IL273704B2 (https=)
MX (1) MX2020003377A (https=)
PL (1) PL3694522T3 (https=)
PT (1) PT3694522T (https=)
TW (1) TWI841539B (https=)
WO (1) WO2019074826A2 (https=)
ZA (1) ZA202002263B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3920927A1 (en) * 2019-02-05 2021-12-15 VIIV Healthcare Company Method for treating hiv with dolutegravir and lamivudine
WO2021116244A1 (en) * 2019-12-12 2021-06-17 Sandoz Ag Modulation of drug release and bioavailability of compositions containing dolutegravir sodium and other anti hiv drugs
CN111991558B (zh) * 2020-08-28 2022-08-09 安徽贝克生物制药有限公司 一种抗逆转录病毒药物组合物及其制备方法
CN114191404B (zh) * 2022-01-10 2023-06-27 安徽贝克生物制药有限公司 一种多替拉韦片剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2744019C (en) 2008-12-11 2017-03-14 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
US9713622B2 (en) * 2009-11-20 2017-07-25 Université Versailles Saint-Quentin-En-Yvelines Schedules for administering combination therapies useful for treating persons afflicted with the human immunodeficiency virus (HIV)
PE20121524A1 (es) * 2010-01-27 2012-12-03 Viiv Healthcare Co Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapeuticos
US20170189402A1 (en) * 2012-03-28 2017-07-06 Abbvie Inc. Solid dosage forms
CA2885763C (en) * 2012-10-23 2021-04-06 Cipla Limited Pharmaceutical antiretroviral composition
WO2014184553A1 (en) 2013-05-15 2014-11-20 Cipla Limited Pharmaceutical antiretroviral compositions
US10189860B2 (en) * 2014-07-29 2019-01-29 Lek Pharmaceuticals D.D. Hydrates of dolutegravir sodium
CN106860464A (zh) * 2017-02-16 2017-06-20 江苏艾迪药业有限公司 用于联合抗病毒治疗的药物组合物及应用

Similar Documents

Publication Publication Date Title
AT524874A5 (https=)
JP2020536931A5 (https=)
AU2018438767B1 (https=)
AT524961A5 (https=)
BR112020012832A2 (https=)
BR202018071071U8 (https=)
BR102018070765A2 (https=)
BR102018016915A2 (https=)
BE2018C025I2 (https=)
BR202018008879U2 (https=)
BR202018007669U2 (https=)
BR102018007062A2 (https=)
BR202018006247U2 (https=)
BR202018004136U2 (https=)
BR202018002487U2 (https=)
BR202018002069U2 (https=)
CN304439680S (https=)
CN304388867S9 (https=)
CN304435135S (https=)
CN304434154S (https=)
CN304434153S (https=)
CN304434112S (https=)
CN304434110S (https=)
CN304435982S (https=)
CN304436082S (https=)